Skip to main
VYGR
VYGR logo

Voyager Therapeutics (VYGR) Stock Forecast & Price Target

Voyager Therapeutics (VYGR) Analyst Ratings

Based on 20 analyst ratings
Buy
Strong Buy 45%
Buy 40%
Hold 15%
Sell 0%
Strong Sell 0%

Bulls say

Voyager Therapeutics Inc. is positioned positively due to its co-commercialization options for key programs, which could significantly enhance long-term revenue potential through the successful validation of its TRACER capsids in clinical settings. The company's robust pipeline, which includes novel gene therapy candidates targeting severe neurological diseases, is supported by an absence of serious adverse events, thereby strengthening the safety profile of its therapies. Additionally, the termination of the VY9323 program has extended Voyager's cash runway into mid-2027, allowing the company to concentrate on its promising Alzheimer's programs and potentially introduce innovative, lower-dose alternatives to existing treatments, thereby creating substantial value for shareholders.

Bears say

Voyager Therapeutics Inc. faces significant financial challenges, including a lack of sales revenue and a projected lengthy timeline before it reaches profitability, potentially extending several years. The company reported a net loss of ($1.13) per share, which raises concerns about valuation estimates and revenue projections, particularly in light of potential delays or denials in regulatory approvals for its key therapeutic candidates. Additionally, intense competition in the gene therapy space, coupled with the high risk of failure in clinical studies for its programs, further exacerbates the negative outlook on Voyager's stock performance.

Voyager Therapeutics (VYGR) has been analyzed by 20 analysts, with a consensus rating of Buy. 45% of analysts recommend a Strong Buy, 40% recommend Buy, 15% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Voyager Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Voyager Therapeutics (VYGR) Forecast

Analysts have given Voyager Therapeutics (VYGR) a Buy based on their latest research and market trends.

According to 20 analysts, Voyager Therapeutics (VYGR) has a Buy consensus rating as of Jul 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $17.54, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $17.54, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Voyager Therapeutics (VYGR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.